- Home
- SOAR vs ADXN Comparison
SOAR vs ADXN Comparison
Compare SOAR & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SOAR | ADXN |
|---|---|---|
| Founded | 2021 | 2002 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5M | 10.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SOAR | ADXN |
|---|---|---|
| Price | $0.67 | $7.88 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.2M | 3.2K |
| Earning Date | 11-13-2025 | 12-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.32 | N/A |
| Revenue | ★ $58,312,000.00 | $198,824.00 |
| Revenue This Year | N/A | $86.57 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.58 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.59 | $6.51 |
| 52 Week High | $7.25 | $12.05 |
Technical Indicators
Market Signals| Indicator | SOAR | ADXN |
|---|---|---|
| Relative Strength Index (RSI) | 31.97 | 47.69 |
| Support Level | $0.59 | $7.74 |
| Resistance Level | $0.79 | $8.90 |
| Average True Range (ATR) | 0.13 | 0.39 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 10.53 | 28.56 |
Price Performance
Historical ComparisonAbout SOAR Volato Group Inc.
Volato Group Inc operates an aircraft ownership program, provides ad-hoc charter flights, sells deposit products, and manages aircraft for owners in the private aviation industry. It offers fractional ownership, aircraft management, jet cards, deposit, and charter programs. The company's fractional programs provides flexible hours and a revenue share for owners in a fleet of HondaJets, optimized for missions of up to four passengers.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.